pd 173074 has been researched along with Stomach Neoplasms in 8 studies
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Up to 10 % of primary gastric cancers are characterized by FGFR2 amplification, and fibroblast growth factor receptor (FGFR) inhibitors may represent therapeutic agents for patients with these malignancies." | 1.43 | Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. ( Bujak, A; Dymek, B; Dzwonek, K; Grygielewicz, P; Gunerka, P; Lamparska-Przybysz, M; Stanczak, A; Wieczorek, M; Zdzalik, D, 2016) |
| "Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood." | 1.40 | Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. ( Arai, Y; Furuta, K; Hama, N; Hosoda, F; Kosuge, T; Nakamura, H; Ojima, H; Okusaka, T; Shibata, T; Shimada, K; Shirota, T; Totoki, Y, 2014) |
| "MKN45, a gastric cancer cell line, was treated with each single agent alone or a combination of FGF19, PD and 5-Fu." | 1.39 | Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. ( Hu, S; Shi, YQ; Wang, GJ; Wen, JG; Ye, YW; Zhang, XF; Zhao, CL; Zhou, Y; Zong, H, 2013) |
| "In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively in FGFR2-amplified cell lines KatoIII, Snu16, and OCUM-2M." | 1.35 | FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. ( Davis, L; Di Bacco, A; Elbi, C; Gorenstein, J; Hatch, H; Kunii, K; Lutterbach, B; Yashiro, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y | 1 |
| Totoki, Y | 1 |
| Hosoda, F | 1 |
| Shirota, T | 1 |
| Hama, N | 1 |
| Nakamura, H | 1 |
| Ojima, H | 1 |
| Furuta, K | 1 |
| Shimada, K | 1 |
| Okusaka, T | 1 |
| Kosuge, T | 1 |
| Shibata, T | 1 |
| Ye, YW | 1 |
| Hu, S | 1 |
| Shi, YQ | 1 |
| Zhang, XF | 1 |
| Zhou, Y | 2 |
| Zhao, CL | 1 |
| Wang, GJ | 1 |
| Wen, JG | 1 |
| Zong, H | 1 |
| Liu, YJ | 1 |
| Shen, D | 1 |
| Yin, X | 1 |
| Gavine, P | 1 |
| Zhang, T | 1 |
| Su, X | 1 |
| Zhan, P | 1 |
| Xu, Y | 1 |
| Lv, J | 1 |
| Qian, J | 1 |
| Liu, C | 1 |
| Sun, Y | 1 |
| Qian, Z | 1 |
| Zhang, J | 2 |
| Gu, Y | 1 |
| Ni, X | 1 |
| Grygielewicz, P | 1 |
| Dymek, B | 1 |
| Bujak, A | 1 |
| Gunerka, P | 1 |
| Stanczak, A | 1 |
| Lamparska-Przybysz, M | 1 |
| Wieczorek, M | 1 |
| Dzwonek, K | 1 |
| Zdzalik, D | 1 |
| Li, J | 1 |
| Ye, Y | 1 |
| Wang, M | 1 |
| Lu, L | 1 |
| Han, C | 1 |
| Yu, Z | 1 |
| Zhang, X | 1 |
| Zhao, C | 1 |
| Wen, J | 1 |
| Kan, Q | 1 |
| Matsumoto, K | 1 |
| Arao, T | 1 |
| Hamaguchi, T | 1 |
| Shimada, Y | 1 |
| Kato, K | 1 |
| Oda, I | 1 |
| Taniguchi, H | 1 |
| Koizumi, F | 1 |
| Yanagihara, K | 1 |
| Sasaki, H | 1 |
| Nishio, K | 1 |
| Yamada, Y | 1 |
| Chell, V | 1 |
| Balmanno, K | 1 |
| Little, AS | 1 |
| Wilson, M | 1 |
| Andrews, S | 1 |
| Blockley, L | 1 |
| Hampson, M | 1 |
| Gavine, PR | 1 |
| Cook, SJ | 1 |
| Kunii, K | 1 |
| Davis, L | 1 |
| Gorenstein, J | 1 |
| Hatch, H | 1 |
| Yashiro, M | 1 |
| Di Bacco, A | 1 |
| Elbi, C | 1 |
| Lutterbach, B | 1 |
8 other studies available for pd 173074 and Stomach Neoplasms
| Article | Year |
|---|---|
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Topics: Adenosylhomocysteinase; Aged; Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hep | 2014 |
Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
Topics: Apoptosis; bcl-X Protein; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2013 |
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; | 2014 |
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchym | 2016 |
The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Flu | 2016 |
FGFR2 gene amplification and clinicopathological features in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cohort Studies; Female; Gene Amplification; Gene D | 2012 |
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe | 2013 |
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Topics: Apoptosis; Cell Growth Processes; Cell Line, Tumor; Gene Amplification; Humans; Phosphorylation; Pyr | 2008 |